Belay Vantage™
MGMT promoter methylation in CSF
An advanced approach to determining MGMT promoter methylation status
Belay Vantage uses quantitative polymerase chain reaction to evaluate MGMT promoter methylation in cerebrospinal fluid of individuals with known or suspected central nervous system tumors.
Why choose Belay Vantage?
- Analysis in CSF sample is less invasive than brain biopsy
- Assay uses a highly effective enzymatic conversion method, minimizing DNA damage1
- Vantage™ can be ordered concomitantly with Summit™ testing, using same patient specimen
- Collection of CSF is well tolerated and included in the standard of care for many patients with suspicion of CNS tumors
- Turnaround time is average 7-10 business days from receipt of specimen
- New England Biolabs, Inc. NEBNext® Enzymatic Methyl-seq (EM-seq™). Updated April 2019. Accessed May 20, 2024.